Drug Profile
OMO 1
Alternative Names: DO-1; JNJ-38877618; OMO-1Latest Information Update: 30 Nov 2023
Price :
$50
*
At a glance
- Originator Janssen Pharmaceutica
- Developer Janssen-Cilag; Octimet Oncology
- Class Antineoplastics; Pyridazines; Pyridines; Quinolines; Small molecules; Triazoles
- Mechanism of Action Organic cation transporter 2 inhibitors; Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- No development reported Cancer
Most Recent Events
- 30 Nov 2022 OMO 2 licensed to DeuterOncology worldwide excluding greater China (DeuterOncology pipeline, March 2023)
- 16 Sep 2020 OMO 1 licensed to Allist Pharmaceuticals in HongKong, Macau, China and Taiwan
- 16 Sep 2020 Allist pharmaceuticals plans a clinical trial (Combination therapy) for Non-small cell lung cancer